Brief: Immunome And Morphimmune Announce Definitive Merger Agreement And Simultaneous Private Placement Investment Of $125 Million To Develop Targeted Cancer Therapies

Immunome

29/06/2023 14:40

June 29 (Reuters) - Immunome Inc  IMNM.O :
    * IMMUNOME AND MORPHIMMUNE ANNOUNCE DEFINITIVE MERGER
AGREEMENT
AND SIMULTANEOUS PRIVATE PLACEMENT INVESTMENT OF $125 MILLION TO
DEVELOP TARGETED CANCER THERAPIES
    * IMMUNOME INC-COMBINED COMPANY, WHICH WILL OPERATE AS
IMMUNOME
    * IMMUNOME INC-CLAY B. SIEGALL MORPHIMMUNE PRESIDENT & CEO
TO
SERVE AS CHAIRMAN AND CEO OF COMBINED COMPANY
    * IMMUNOME INC-WILL ACQUIRE MORPHIMMUNE THROUGH REVERSE
SUBSIDIARY
MERGER THAT IS INTENDED TO BE A TAX-FREE REORGANIZATION
    * IMMUNOME INC-STOCKHOLDERS OF MORPHIMMUNE WILL RECEIVE
COMMON
STOCK OF IMMUNOME
    * IMMUNOME INC-AT EFFECTIVE TIME OF MERGER,  SECURITYHOLDERS
OF
IMMUNOME WILL OWN ABOUT 55% OF COMBINED CO
    * IMMUNOME INC-AT EFFECTIVE TIME OF MERGER,  SECURITYHOLDERS
OF
MORPHIMMUNE WILL OWN ABOUT 45% OF COMBINED CO ON FULLY DILUTED
BASIS
    * IMMUNOME INC- FOLLOWING PROPOSED MERGER BOARD OF DIRECTORS
OF
COMBINED CO WILL BE COMPRISED OF SEVEN MEMBERS
    * IMMUNOME -CONCURRENT $125 MILLION PRIVATE PLACEMENT WILL
SUPPORT
DEVELOPMENT OF COMBINED PIPELINE EXPECTED TO SUBMIT 3 INDS
WITHIN 18 MONTHS OF CLOSING

Source text for Eikon:  ID:nBw2kKvFa 
Further company coverage:  IMNM.O 

 ((Reuters.Briefs@thomsonreuters.com;))